RE:You think?
Eoganacht wrote: “We believe Ruvidar has the potential to achieve a better and longer duration of complete response (CR) than Merck’s Keytruda,” writes analyst Andre Uddin. | | Complete Response Rates |
| | Keytruda | TLD1433 |
| 3 months | 41% | 60% |
| 12 months | 19% | 31% |
| 15 months | | 30% |
| 18 months | 13% | |
| 24 months | 9% | |
If I were Pfizer or any Big Pharma not named Merck, I would swoop in for the taking before Merck fully wakes up & realizes the huge opportunity sitting in their own lap (considering their own subsidiary, Sigma-Aldrich, synthesizes Ruvidar/TLD-1433). Having plenty of experience now with Keytruda, which has enabled them to practically corner the cancer immunotherapy market, Merck is well aware of checkpoint inhibitors' (CIs) limitations (i.e. a significant portion of the population is simply less responsive to CIs, which is genetically determined), & being able to fill this treatment gap with an ACT such as ours would give them a 2nd silver bullet (perhaps shinier) in the fight against cancers with high unmet need...a specific area they have been targeting more in recent years.
We have successfully navigated some pretty rough seas, & it's only a matter of time before we either awaken the Kraken/Merck or a great whale comes to the feast first...perhaps even a smaller suitor. It's nice to know we have the most appetizing bait on our hook.